Squarepoint’s iBio IBIO Stock Holding History

Squarepoint’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-178	Closed	-$49K	–	3152
2021 Q4	$49K	Sell	178 -530	-75%	-$202K	﹤0.01%	3023
2021 Q3	$375K	Sell	708 -260	-27%	-$162K	﹤0.01%	2134
2021 Q2	$731K	Buy	+968	New	+$706K	﹤0.01%	1852
2020 Q3	–	Sell	-37	Closed	-$42K	–	2643
2020 Q2	$42K	Buy	+37	New	+$24.2K	﹤0.01%	2112

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Squarepoint's IBIO Position: Q1 2022 in Review

Squarepoint sold out of iBio (IBIO) in Q1 2022, closing a stake of 178 shares — an estimated $49K sold.

Squarepoint first reported a position in IBIO in Q2 2020 and held it in 4 quarters. The position peaked at $731K in Q2 2021. 70 funds tracked by Wall St. Rank hold IBIO as of Q1 2022.

Squarepoint reported no remaining iBio position as of Q1 2022 after selling out during the quarter.
Squarepoint sold 178 iBio shares in Q1 2022, an estimated $49K.
Squarepoint first reported a position in iBio in Q2 2020 and held it in 4 quarters.
Squarepoint's iBio position peaked at $731K in Q2 2021.
70 funds tracked by Wall St. Rank held iBio as of Q1 2022.

Based on Squarepoint's 13F filing for Q1 2022, filed 16 May 2022.